Todd A. Huffman
Fondateur chez Padlock Therapeutics, Inc.
Profil
Todd A.
Huffman is the founder of Padlock Therapeutics, Inc., which was founded in 2014.
He holds the title of Director at Padlock Therapeutics, Inc. Dr. Huffman is currently working as the Director-Clinical Translation Initiative at The University of Virginia School of Medicine.
Dr. Huffman previously worked as an Analyst at RCT BioVentures from 2007 to 2010.
Dr. Huffman obtained a doctorate degree from the University of Virginia in 2005.
Postes actifs de Todd A. Huffman
| Sociétés | Poste | Début |
|---|---|---|
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Fondateur | 01/01/2014 |
| The University of Virginia School of Medicine | Corporate Officer/Principal | - |
Anciens postes connus de Todd A. Huffman
| Sociétés | Poste | Fin |
|---|---|---|
RCT BioVentures
 RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona. | Analyste en capital-investissement | 30/03/2010 |
Formation de Todd A. Huffman
| University of Virginia | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
RCT BioVentures
RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona. | Finance |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Health Technology |